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tivity of 82% and speciﬁcity of 75%. Taken together, these data
demonstrate that molecular proﬁles can be generated which are
highly predictive of different levels of radiation exposure in
mice and humans. We suggest that this approach, with addi-
tional reﬁnement, could provide a method to assess the effects of
various environmental inputs into biological phenotypes as well
as providing a more practical application of a rapid molecular
screening test for the diagnosis of radiation exposure.
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HIGH PREVALENCE OF BONE LOSS IN LONG TERM SURVIVORS FOL-
LOWING ALLOGENEIC BONE MARROW AND PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION
Donohue, T.B.1, Savani, B.N.1, Shenoy, A.1, Kozanas, E.1,
Singh, A.K.2, Childs, R.W.1, Barrett, A.J.1 1Stem Cell Transplant
Secotion, Hematology Branch; NHLBI, National Institutes of Health,
Bethesda, MD; 2Radiation Biology Section; NCI, National Institutes of
Health, Bethesda, MD.
Bone loss (osteopenia/osteoporosis) is a complication following
allogeneic stem cell transplantation (SCT). After written consent
patients surviving more than three years post-transplant were en-
rolled in a long-term follow-up study (started in April 2005) which
included an annual DEXA scan. Sixty-three patients (median age
35 years) received a fractionated total body irradiation (TBI) (12-
13.6 Gy) based myeloablative SCT (MST) and 9 patients (median
age 37 years) received a non-TBI non-myeloablative SCT (NST).
Age of patients at transplantation ranged from 6 to 66 (median 35
years). The indication for SCT was CML (43), MDS (11), AML
(11), ALL (3), CLL (2), SAA (1), and mastocytosis (1). Seventy-two
(41M,31F) patients underwent DEXA scanning. Seventy (97%)
patients are alive at a median follow-up of 73 months (range
32-155); Acute graft versus host disease (GVHD) occurred in 41
(57%) patients and chronic GVHD in 61 (85%). Twelve (17%)
patients at a median follow up 37 (range 32-106 months) were
receiving immunosuppressive therapy (IST) for chronic GVHD at
the time of analysis. All patients were advised to take vitamin D and
calcium supplements after transplantation and all but one female
were taking hormone replacement therapy at the time of DEXA
scanning. Fifty-three (74%) of patients had bone loss in at least one
site measured - 30 (42%) with osteopenia and 23 (32%) with
osteoporosis. There was a preponderance of osteopenia and osteo-
porosis in typical sites such as AP spine (22% and 18%); femoral
neck (46% and 6%); and femur (Ward’s area) (38% and 8%); total
hip (36% and 1%); but also in the forearm (24% and 13%) likely
related to steriod therapy. Mean T score of adult patients was
-1.8  0.16 (male -1.9  0.2; female -1.6  0.3); while mean Z
score of 5 children (age 18) was -1.6  0.45. Factors associated
with signiﬁcant increase risk of bone loss were: age more than
median (p0.03) and prolonged IST (12/12 vs. 41/60; p0.017 for
bone loss and 8/12 vs.15/60; p0.008 for osteoporosis). When
patient age was analyzed by quartiles, the oldest quartile (range
44-66) was profoundly impacted for osteoporosis (mean T score
-2.3 0.25; p0.016). There was no signiﬁcant difference in bone
loss with regard to sex, stem cell source, disease, TBI dose, acute
GVHD, or chronic GVHD. In summary, we found a very high
prevalence of bone loss in long term survivors of SCT. Bone loss
is associated with older age at transplant and continuing treatment
of chronic GVHD.
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Gavamzadeh, A.1, Ali Mogaddam, K.1, Nedaeifard, L.1, Jahani, M.1,
Mousavi, A.1, Iravani, M.1, Bahar, B.1, Khodabandelu 1 Hematology-
Oncology and BMT Research Center, Tehran University of Medical
Sciences, Tehran, Islamic Republic of Iran.
Objective: Beta Thalassemia Major is the most common type of
haemoglobinopathies in Iranian patients. We reported results of 15
years HSCT in our centre.
Method: 277 Beta Thalassemia Major Patients, 158 male and
119 female with median age of 6 years old (range 2.5-26 y), have
been transplanted from 1991 till march 2006 in our centre.
92 patients were class one, 103 class two and 74 class three
according to Dr.Lucarelli classiﬁcation. They have received
allogeneic transplantation from 266 HLA full matched siblings
and 11 other relatives. Source of hematopoietic cells were 136
bone marrow, 133 peripheral blood and 8 cord blood. The most
common conditioning regimen was Bu/Cy without TBI and
their GVHD prophylaxis regimen was Cyclosporine  Metho-
traxate.
Results: 229 (82.7%) patients are alive and 48 (17.3) dead.
Acute GVHD occurred in 61.3% patients and chronic GVHD
in 4.7% patients and both type in 34% patients. Graft rejection
occurred in 60 (21.7%) patients. The most common cause of
death was acute and chronic GVHD. Venooclussive disease
occurred in 17 patients. Five years overall (OS) and thalassemia
free survival (DFS) were 79% and 65% respectively. OS and
DFS of transplanted patients from HLA- identical siblings were
better than transplanted patients from other relatives’ donors.
There were not any signiﬁcant differences in OS of patients in
different classes of disease or sources of HCT. But DFS of class
one was better than three. OS and DFS were better in patients
with acute GVHD and older donors.
Conclusion: HCT based on our experience and other docu-
mented studies is acceptable treatment for Beta Thalassemia
Major with better result in younger patients.
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TRANSPLANTATION, THE IMPORTANCE OF TOTAL BODY IRRADIATION
Ghavamzadeh, A.1, Samiee, S.1, Mahdavi, N.1, Bakhti, O.1,
Jahani, M.1, Alimoghaddam, K.1, Iravani, M.1, Bahar, B.1,
Khodabandeh, A.1, Mousavi, A.1 1Hematology-Oncology and BMT Re-
search Center, Tehran University of Medical Sciences, Tehran, Islamic
Republic of Iran.
Purpose: In this study we studied the records of 1586 recipi-
ents of autologous or allogeneic-related and -unrelated and
syngeneic bone marrow transplants (BMTs) between 1991 till
2006 to determine the incidence of secondary malignancies and
importance of Total Body Irradiation as a risk factor.
PATIENTS AND METHODS : 829 patients were under-
gone transplantation for acute lymphocytic leukemia (ALL; n 
212), acute myelogenous leukemia (AML; n  429), and chronic
myelogenous leukemia (CML; n  188) while 162 patients for
Lymphoma, 98 for aplastic anemia (AA), 284 for Thalassemia
and 213 patients for a variety of other hematologic and nonhe-
matologic disorders, malignant and nonmalignant. Condition-
ing regimens included high-dose chemotherapy without total-
body irradiation (TBI). Patients who were missed to follow-up
were excluded from the study on the time of missed to follow up.
RESULTS: 9 patients developed 9 secondary cancers for a one
year risk of 1.2%, ﬁve year risk of 2.4% and ten year risk of
2.9%. Of all the 9 patients 5 (55.5) were male, and 4(44.4%)
were female. The median age was 21 years old; with minimum
and maximum of 13 and 28 y/o respectively. 6(66.6%) patients
received allogeneic stem cell transplantation and 3(33.3%) re-
ceived autologous transplantation. 5 patients (55.5%) had pe-
ripheral blood as graft type. The conditioning regimen for
4(44.4%) of patients was Busulphan and Cyclophosphamide, 1
patient had Busulphane, Cyclophosphamide and Etoposide, 3 of
them had Cyclophosphamide, Etoposide and Ara-C. The other
1 patient had ATG, Cyclophosphamaide and Fludarabine as
conditioning regimen. The median follow-up duration for all
our patients was 376 days, (1-4749) which was 300 days for these
9 patients who developed new malignancy. (45-1125) .Overall
Mortality Rate is 66.6% and the cause of death in 33.3% of
patients is new malignancy.
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